ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Carrier-Free Stimulus-Responsive Theranostic Nanoprodrug Enabling GSH-Consumption-Promoted Chemo-Photodynamic Cancer Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Synergistic chemo-photodynamic therapy has been proven more effective for cancer treatment compared to traditional chemotherapy and photodynamic therapy alone. Leveraging the characteristic of cancer cells that glutathione (GSH) plays an indispensable role in the development of drug resistance and reactive oxygen species (ROS) neutralization, we developed a carrier-free GSH-consuming theranostic nanoprodrug to deeply explore the GSH-consumption-promoted synergistic chemo-photodynamic therapy for boosted cancer treatment. The GSH-consuming nanoprodrug consists of paclitaxel (PTX) and a boron-dipyrromethene (BODIPY)-based photosensitizer, linked through a GSH-responsive self-immolating drug linkage; to serve as a control, a non-GSH-consuming nanoprodrug consisting of those two moieties linked by a non-biocleavable linkage was also developed. The carrier-free nanoprodrugs have a diameter of ∼65 nm and an ultrahigh drug loading content (>70%), and have exhibited highly efficient suppression against tumor proliferation upon light irradiation to trigger their photodynamic effect, more potent than the free PTX drug, because of the synergistic chemo-photodynamic therapy. Attractively, the GSH-consuming theranostic nanoprodrug, in comparison with its non-GSH-consuming counterpart, exerted extraordinarily powerful therapeutic effects, benefiting from its integrated advantages, including GSH-activated traceless PTX release, reduced drug resistance, and disabled ROS neutralization of cancer cells due to the consumption of intracellular GSH, resulting in the ultimate eradication of tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.